Radical treatment for high-risk prostate cancer among older men in Sweden according to life expectancy estimates

by K. Beckmann, J. Adolfsson, M. Van Hemelrijck, D. Robinson, P. Stattin, H. Garmo
Published 2020-07-01

Radiotherapy treatment for prostate cancer in Sweden: Patterns over 20 years

by K. Beckmann, H. Garmo, M. Van Hemelrijck, P. Nilsson, I. Franck Lissbrant, P. Stattin
Published 2020-07-01

Extent of lymph node dissection: Effect on post-operative outcomes following radical cystectomy

by C.L. Moss, B. Russell, M. Van Hemelrijck, S. Malde, R. Nair, R. Thurairaja, M.S. Khan
Published 2020-07-01

The effect of active surveillance on patient-reported erectile and urinary function. Results of the Movember Foundation’s GAP3 cohort

by T. Crump, S. Remmers, M. Van Hemelrijck, J. Helleman, D. Nieboer, M.J. Roobol, L.D.F. Venderbos
Published 2020-07-01

Spironolactone use is associated with lower risk of prostate cancer

by K. Beckmann, H. Garmo, B. Lindahl, L. Holmberg, P. Stattin, J. Adolfsson, K. Cruickshank, M. Van Hemelrijck
Published 2020-07-01

Real World Evidence: A Quantitative and Qualitative Glance at Participant Feedback from a Free-Response Survey Investigating Experiences of a Structured Exercise Intervention for M...

by L. Fox, F. Cahill, C. Burgess, N. Peat, S. Rudman, J. Kinsella, D. Cahill, G. George, A. Santaolalla, M. Van Hemelrijck
Published 2017-01-01

PIONEER’s systematic review of outcomes in RCTs of men with non-metastatic castration resistant prostate cancer: Is there a need for a core outcome set?

by K. Beyer, S. MacLennan, M. Lardas, L. Moris, E. Vradi, M.I. Omar, S.J. MacLennan, A. Briganti, M. Van Hemelrijck
Published 2020-07-01

A first step towards a global nomogram to predict disease progression for men on active surveillance

by M. Van Hemelrijck, X. Ji, J. Helleman, M. Roobol, D. Nieboer, C. Bangma, M. Frydenberg, A. Rannikko, L-S. Lee, V. Gnanapragsam, M. Kattan
Published 2020-07-01

Is it time to revise active surveillance protocols for men on active surveillance who have negative prostate findings on re-biopsy?

by K. Beckmann, S. Singh, P. Sandhu, A. Santa Olalla, K. Dewan, P. Cathcart, B. Challacombe, R. Poppert, P. Dasgupta, M. Van Hemelrijck, O. Elhage
Published 2020-07-01

PIONEER consensus on clinician reported outcome measurements

by K. Beyer, L. Moris, G. Gandaglia, M. Lardas, J. Healey, M.I. Omar, J. Zong, S.J. Maclennan, A. Briganti, M. Van Hemelrijck, S. Maclennan
Published 2020-11-01

Guy’s cancer cohort – real world evidence for cancer pathways

by C. Moss, A. Haire, F. Cahill, D. Enting, S. Hughes, D. Smith, E. Sawyer, A. Davies, J. Zylstra, K. Haire, A. Rigg, M. Van Hemelrijck
Published 2020-03-01

Protocol adherence and outcomes among African/Afro-Caribbean men on active surveillance for prostate cancer

by K. Beckmann, H. Aya, A. Santa Olalla, P. Sandu, S. Singh, M. Nikhil, P. Cathcart, B. Challacombe, R. Poppert, P. Dasgupta, M. Van Hemelrijck, O. Elhage
Published 2020-07-01

King’s Health Partners’ Prostate Cancer Biobank (KHP PCaBB)

by S. R. Saifuddin, W. Devlies, A. Santaolalla, F. Cahill, G. George, D. Enting, S. Rudman, P. Cathcart, B. Challacombe, P. Dasgupta, C. Galustian, A. Chandra, S. Chowdhury, C. Gillett, M. Van Hemelrijck
Published 2017-11-01

Understanding the bladder cancer patients experience: What are the needs?

by A. Bessa, C. Bosco, F. Cahill, B. Russell, L. Fox, C. Moss, H. Wylie, A. Haire, S. Green, D. Enting, S. Broadhead, M. Northover, K. Chatterton, S. Amery, N. Peat, S. Smith, C. Haggstrom, M. Van Hemelrijck
Published 2020-07-01

PIONEER’s operational definitions: Harmonising clinical characteristics and phenotypes data of prostate cancer patients

by K. Beyer, L. Moris, M. Lardas, G. Gandaglia, M. Roobol, A. Bjartell, M.I. Omar, R. Herrera, S. Maclennan, E. Smith, J. Zong, T. Hofmarcher, N. Zounemat Kermanin, S.J. Maclennan, A. Briganti, C. Reich, B. Meulder, M. Van Hemelrijck
Published 2020-11-01

Identifying the most appropriate instrument for Patient-Reported Outcome Measures (PROMs) in patients with clinically localised prostate cancer

by M.M. Ratti, G. Gandaglia, L. Leardini, S. Mazzoleni Ferracini, E.S. Sisca, A. Derevianko, F. Furnari, K. Beyer, F. Pellegrino, G. Sorce, F. Barletta, S. Scuderi, M.I. Omar, S. Maclennan, J. Zong, S.J. Maclennan, O.L. Aiyegbusi, M. Van Hemelrijck, J. N’Dow, A. Briganti
Published 2020-11-01

PIONEER: European Commission Innovative Medicines Initiative funded BD4BO (Big data for better outcome) project on prostate cancer

by S. Evans Axelsson, T. Abbott, L. Fullwood, M.I. Omar, M. Cavelaars, A. Asiimwe, M. Roobol, M.J. Ribal, C. Auffray, Z. Devecseri, E.J. Smith, M. Van Hemelrijck, S. MacLennan, D. Horgan, C. Reich, B. De Meulder, D. Lancet, C. Bangma, A. Briganti, D. Tilki, H. Van Poppel, M.P. Wirth, J. N’Dow, A. Bjartell
Published 2020-07-01

Initial steps of an online search tool development for diagnostic and prognostic factors in prostate cancer

by K. Beyer, L. Moris, M. Lardas, A. Haire, F. Barletta, S. Scuderi, M. Molnar, R. Herrera, A. Rauf, R. Campi, I. Greco, K. Shiranov, S. Dabestani, T.B. Van Den Broeck, A. Sujenthiran, M. Gacci, G. Gandaglia, M.I. Omar, S. Maclennan, M. Roobol, B. Farahmand, E. Vradi, Z. Devecsero, A. Asiimwe, J. Zong, S.J. Maclennan, L. Collette, J. N’dow, A. Briganti, A. Bjartell, M. Van Hemelrijck
Published 2020-11-01

Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus

by W. R. C. Knight, C. Yip, W. Wulaningsih, A. Jacques, N. Griffin, J. Zylstra, M. Van Hemelrijck, N. Maisey, A. Gaya, C. R. Baker, M. Kelly, J. A. Gossage, J. Lagergren, D. Landau, V. Goh, A. R. Davies, on behalf of the Guy's and St Thomas' Oesophago‐Gastric Research Group, S. Ngan, A. Qureshi, H. Deere, M. Green, F. Chang, U. Mahadeva, B. Gill‐Barman, S. George, J. Dunn, S. Zeki, J. Meenan, O. Hynes, G. Tham, C. Iezzi
Published 2019-12-01